Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T® Therapy SV-102 for Patients with Metastatic Castration-Resistant Prostate CancerSYNC-T Therapy SV-102 combines partial tumor oncolysis with a multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic solid tumor cancersFORT LAUDERDALE, Fla. and...
Category: 2025
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual MeetingStudy Demonstrated 87% Overall Response Rate in Metastatic Prostate Cancer Patients Treated with SYNC-T, a First-in-Class In Situ Personalized Immunotherapy Platform Abstract published on podium presentation that will take place...
Syncromune® Inc. to Present Clinical Data from SYNC-T Therapy SV-102 Phase 1 Trial at the American Society for Clinical Oncology Annual Meeting 2025
Syncromune® Inc. to Present Clinical Data from SYNC-T Therapy SV-102 Phase 1 Trial at the American Society for Clinical Oncology Annual Meeting 2025FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, March 25, 2025 (GLOBE NEWSWIRE) --Syncromune®, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination...
Syncromune Appoints Zhihong Li, Ph.D., as Chief Regulatory Affairs Officer to Lead Global Regulatory Strategy for Novel Oncology Immunotherapies
Syncromune Appoints Zhihong Li, Ph.D., as Chief Regulatory Affairs Officer to Lead Global Regulatory Strategy for Novel Oncology ImmunotherapiesFORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, March 25, 2025 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company developing SYNC-T, an in situ personalized immunotherapy platform optimized for solid tumor cancers, today announced...
